Evercore ISI raised the firm’s price target on Cardinal Health (CAH) to $180 from $175 and keeps an Outperform rating on the shares after attending the company’s Investor Day event. Cardinal’s long-term guidance remains unchanged, and Evercore ISI sees continued potential upside to the firm’s estimates given the company’s strong execution, deployment of improved free cash flow, and multipronged growth outlook with particular potential upside from specialty, nuclear/other, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Oracle reports Q4 beat, BioNTech to acquire CureVac: Morning Buzz
- Morning Movers: CureVac skyrockets after $1.25B deal to be acquired by BioNTech
- Cardinal Health Updates FY25 Outlook and FY26 Guidance
- Cardinal Health raises FY25 EPS view to $8.15-$8.20 from $8.05-$8.15
- Cardinal Health sees FY26 EPS $9.10-$9.30, consensus $9.13